DEFINING MECHANISTIC TARGETS AND CIRCULATING BIOMARKERS OF THERAPEUTIC RESPONSE AND RESISTANCE TO CLINICAL ATR AND CHK1 INHIBITORS IN HIGH-GRADE OVARIAN CANCER

Medicine & Life Sciences

1. Ataxia Telangiectasia 100%
2. Ovarian Neoplasms 49%
3. Cyclin-Dependent Kinase 6 47%
4. Biomarkers 32%
5. Proteins 31%
6. Poly(ADP-ribose) Polymerase Inhibitors 17%
7. Therapeutics 9%
8. Proteomics 8%
9. G1 Phase 6%
10. Ubiquitin 6%
11. S Phase 6%